• Explore /
  • Poster
  • / Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

Abstract Poster

Authors

null

Kevin J. Harrington

The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Surrey, United Kingdom

Kevin J. Harrington , Anthony Hee Kong , Nicolas Mach , Tamara Rordorf , Jesus Corral Jaime , Vittoria Espeli , Sheryl Treichel , Burak Gumuscu , Jenny J. Kim , Jason Alan Chesney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02626000

Citation

J Clin Oncol 36, 2018 (suppl; abstr 6036)

DOI

10.1200/JCO.2018.36.15_suppl.6036

Abstract #

6036

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: Steven Francis Powell

First Author: Danny Rischin

First Author: Lillian L. Siu

First Author: David Samuel DiCapua Siegel